American Cancer Society Institutional Research Grant Program
The American Cancer Society Institutional Research Grant (ACS IRG) program is made possible by funds awarded competitively by the American Cancer Society with additional funds provided by the Associate Dean for Research, UC Davis School of Medicine. The Principal Investigator is Primo Lara, Jr., MD, Director, UC Davis Comprehensive Cancer Center.
The ACS IRG award serves as seed money to support initiation of promising new projects or novel investigations in cancer-related fields. Proposals in all areas of cancer research — basic, clinical, epidemiological, behavioral, psychosocial and so on — are welcome. It is hoped that project results can be used as the basis of competitive applications for national funding from the National Cancer Institute, the Society, or similar peer-reviewed extramural sponsors. The Associate Dean for Research, School of Medicine, has provided additional institutional funds for this program.
Junior faculty such as Assistant Professors and researchers with adjunct appointments or in the professional researcher series at the assistant level are eligible. Applicants must be within six years of their initial academic appointment. Faculty in any school or college with cancer-related research are welcome and encouraged to apply. Investigators who have or have had a national peer-reviewed research grant are not eligible.
The call for proposals occurs in the fall with funding beginning January the following year. Maximum funding is currently $36,000 for a one-year project. Award decisions are made intramurally by a committee of UC Davis faculty. Because awards are intramural, they are not processed through Sponsored Programs at the School of Medicine or through the Office of Research.
Call for Applications
Next call for applications will be in the Fall 2018. Announcement of the next IRG call will also be sent through the cancer-program listserv. To subscribe, send an email to firstname.lastname@example.org with "Please add me to the Cancer Center email list" in the subject line.
Questions about the ACS IRG may also be directed to email@example.com.
No current awardees
Using multispectral time-resolved fluorescence spectroscopy to assist surgeons in protecting the parathyroid glands during thyroid surgery.
Surgery in advanced stage non-small cell lung cancer and survival: separating correlation from causation.
Immunotherapy in combination with targeted nanoporphyrin photodynamic therapy for the treatment of bladder cancer.
Large-scale drug repurposing and combination prediction in breast cancer.
A pilot study of live-cell imaging technology to identify drivers of resistant lung cancer cell subpopulations.
A novel targeted antisense approach to double hit lymphomas.
Combined inhibition of FMS-like Tyrosine Kinase 3 (FLT3) and Inhibitors of Apoptosis Proteins (IAP) as a novel approach to the treatment of Acute Myeloid Leukemia (AML).
The Role of RBM38 in Normal and Stress-induced Hematopoiesis.
Dissecting the mechanism of Wnt5a-Ror signaling in cancer metastasis.
Thomas Semrad, M.D., M.A.S.
Pilot Study of Kernel-Based Dynamic 18F-Fludeoxyglucose Positron Emission Tomography (KBD FDG-PET) for Detection of Lymph Node Metastases in Rectal Cancer Patients Treated with Chemoradiation Therapy.
Pulmonary Functional Image-guided Adaptive Radiotherapy for Lung Cancer.
Bridging Kras-Subtype Specific Differences in Tumor Signaling to Targeted Therapeutic Combinations in Lung Cancer Using a Unique Patient-derived Xenograph Resource.
A Dual‐labeling microdosing approach to identify chemoresistance against carboplatin/gemcitabine combination.
Modeling the phenotypic information encoded by ERK and Akt signaling dynamics.
Functional illumination of epigenetic coding in living cells.
Xiaoguang Liu, Ph.D.
Investigation of Novel Microwave Ablation Techniques for Caner Treatment.
The search for novel microbial genetic signatures in aggressive B-cell lymphomas using a comprehensive Microbial Detection Array.
Pilot study of combined radiotherapy and immunotherapy in metastatic canine sarcomas: determining immunologic markers of clinical response
Nagalakshmi Nadiminity, Ph.D.
Regulation of the Lin28/miR-let-7c axis by NF-kappaB2/p52 in prostate cancer.
Targeting Mad3 in Childhood Acute Lymphoblastic Leukemia.
Linking the Gut Microbiome to Cancer.